Atea Pharmaceuticals Achieves Phase 3 Success for BEM/RZR Ahead of NDA Filing

With Phase 3 data now in hand, Atea Pharmaceuticals faces the next critical threshold: translating C-BEYOND's clinical results into a chemistry, manufacturing, and controls (CMC) package capable of supporting an NDA submission for bemnifosbuvir/ruzasvir (BEM/RZR) in chronic hepatitis C virus (HCV) infection. The trial's positive topline readout, announced in July 2026, met its primary non-inferiority endpoint against sofosbuvir/velpatasvir (SOF/VEL) across a 905-patient modified intent-to-treat population.

The enrolled population carries direct implications for manufacturing and labeling strategy. Approximately 89% of C-BEYOND patients were on concomitant medications, roughly 66% carried a comorbid psychiatric diagnosis, and more than 55% reported injection drug use as the transmission route. That profile reinforces the commercial rationale for BEM/RZR's low drug-drug interaction risk and food-effect-free dosing, but it also raises the bar for process validation documentation and post-approval stability commitments that regulators will scrutinize under 21 CFR Part 211 and ICH Q10 quality system expectations.

On efficacy, non-cirrhotic patients (n=721) receiving an 8-week BEM/RZR course achieved a 93.5% sustained virologic response (SVR) rate versus 94.6% for SOF/VEL at 12 weeks, with the 95% confidence interval for the SVR difference falling within the prespecified 5% non-inferiority margin. Cirrhotic patients (n=184) on a 12-week regimen in both arms reached identical 95.4% SVR rates. Virologic failure rates were low and comparable across arms.

For QA and regulatory leads monitoring the pipeline, the parallel C-FORWARD Phase 3 trial, enrolling patients outside North America, remains on schedule with topline results expected in early Q1 2027. That dataset will likely be required to support a global regulatory dossier and will inform comparability assessments if manufacturing sites or processes differ across geographies. Separately, the AT-587 Phase 1 program for hepatitis E virus (HEV) continues to advance into a market with no approved therapies, a gap that shapes both the regulatory pathway and the sterility assurance and formulation demands for any eventual commercial product.

Atea's ability to close the US HCV treatment gap, currently estimated at roughly 85,000 treated annually against an infected population of up to four million, will depend as much on the robustness of its CMC submissions and supply-chain readiness as on the clinical profile C-BEYOND has now established.

Source: Atea Pharmaceuticals via GlobeNewswire, 12 August 2026. Conference call held same day at 4:30 pm ET.